BFB759

Phase 2Biologic

BBluefin Biomedicine, Inc.

BFB759 is one of 7 biologic programs targeting Hidradenitis Suppurativa (HS). It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Hidradenitis Suppurativa (HS)Active, not recruiting

Atopic Dermatitis (AD)Active, not recruiting

Hidradenitis Suppurativa (HS)Preclinical

Active, not recruiting

Atopic Dermatitis (AD)Phase 2

Active, not recruiting

Competition

Competitive Landscape

6 competitors in Hidradenitis Suppurativa (HS)

#DrugCompanyPhaseTrials

Cosentyx

Novartis

Approved

1 2

Povorcitinib

Incyte

Phase 3

3 3

BFB759

BBluefin Biomedicine, Inc.

Phase 2

1 4

Tibulizumab

ZZura Bio Inc

Phase 2

1 5

ORKA-002

OOruka Therapeutics, Inc.

Phase 2

1 6

NAV-240

NNavigator Medicines, Inc.

Phase 2

1 7

Soquelitinib

CCorvus Pharmaceuticals, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Active, not recruiting

Atopic Dermatitis (AD)

NCT07105488

Q3 2027

PreclinicalActive, not recruiting

Hidradenitis Suppurativa (HS)

NCT07287644

Clinical

Trials by Indication[1]

Hidradenitis Suppurativa (HS)1 trial

A Phase 2, Dose Ranging, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of BFB759 in Patients With Moderate to Severe Hidradenitis Suppurativa

Active, not recruiting·BBluefin Biomedicine, Inc.·Preclinical·NCT07287644·210 enrolled

Atopic Dermatitis (AD)1 trial

A Phase 2, Parallel-arm, Randomized, Double-blind, Placebo-controlled, Dose-ranging Study to Evaluate the Efficacy and Safety of BFB759 in Patients With Atopic Dermatitis (COMPASS 2-AD)

Active, not recruiting·BBluefin Biomedicine, Inc.·Phase 2·NCT07105488·225 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for BFB759. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — BFB759 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for BFB759. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Bluefin Biomedicine, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: BBluefin Biomedicine, Inc.

BFB759

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Trials by Indication[1]

Hidradenitis Suppurativa (HS)1 trial

Atopic Dermatitis (AD)1 trial

References

Drug Info

Quick Facts

Related News